Krystal Biotech (KRYS) AI Stock Analysis

• Market Cap: $6.92B
• Dividend Yield: N/A
• Average Volume (3M): 291.36K
• Price to Earnings (P/E): 35.4
• Beta (1Y): 0.76
• Revenue Growth: 54.51%
• EPS Growth: 275.94%
• Country: US
• Employees: 275
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 2.66
• Shares Outstanding: 28,997,519
• 10 Day Avg. Volume: 360,996
• 30 Day Avg. Volume: 291,361
• PEG Ratio: 0.07
• Price to Book (P/B): 4.73
• Price to Sales (P/S): 15.42
• P/FCF Ratio: 37.58
• Enterprise Value/Market Cap: 0.66
• Enterprise Value/Revenue: 12.18
• Enterprise Value/Gross Profit: 12.97
• Enterprise Value/Ebitda: 26.55
• 1Y Price Target: $229.25
• Price Target Upside: -2.78% Downside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 80 Outperform
• Price Target: $269.00 ▲(14.08% Upside)

Krystal Biotech's strong financial performance and successful international expansion are the most significant factors driving the stock's positive outlook. The company's robust earnings call and strategic corporate events further bolster confidence. However, technical indicators suggest caution due to potential short-term overbought conditions, and the high valuation reflects expectations of continued growth.

Positive Factors

Revenue Growth

Strong revenue growth from VYJUVEK indicates successful market penetration and product adoption, supporting long-term financial stability.

International Expansion

Successful international expansion into major markets enhances Krystal Biotech's global footprint and revenue diversification.

FDA Orphan Designation

Orphan designation can accelerate development and approval processes, potentially leading to new revenue streams and market leadership.

Negative Factors

Free Cash Flow Decline

A decline in free cash flow growth may limit the company's ability to invest in new projects and maintain operational flexibility.

Gross Margin Challenges

Challenges in maintaining high gross margins internationally could impact profitability and competitive positioning.

Market Penetration

Incomplete market penetration suggests potential revenue growth is not fully realized, posing a risk to achieving projected sales targets.

Krystal Biotech Business Overview & Revenue Model

Company Description

Krystal Biotech, Inc. is a biotechnology company focused on developing transformative gene therapies for patients with debilitating skin diseases. The company specializes in its proprietary Skin TARGET technology platform, which facilitates the delivery of therapeutic genes to the skin. Krystal Biotech's core products include therapies for conditions such as dystrophic epidermolysis bullosa and other dermatological disorders, aimed at addressing significant unmet medical needs.

How the Company Makes Money

Krystal Biotech generates revenue primarily through the commercialization of its gene therapy products. This includes product sales from approved therapies, which can be substantial given the high demand for effective treatments in rare diseases. Additionally, the company may enter into strategic partnerships with pharmaceutical companies or research institutions to develop and market its products, which can provide upfront payments, milestone payments, and royalties based on future sales. The ongoing development of new therapies and potential expansions into additional markets also contribute to their revenue streams.

Krystal Biotech Financial Statement Overview

Summary

Krystal Biotech demonstrates strong financial health with impressive revenue growth and profitability metrics. The balance sheet is robust with minimal leverage, enhancing financial stability. While cash flow metrics show some decline in free cash flow growth, the company maintains strong cash generation capabilities. Overall, the financial statements reflect a company on a positive growth trajectory with solid operational and financial management.

Income Statement

Krystal Biotech has shown impressive revenue growth with a 3.89% increase in TTM, following a 4.73% growth in the previous year. The company maintains strong profitability with a TTM gross profit margin of 68.78% and a net profit margin of 53.30%. The EBIT and EBITDA margins are also robust at 33.32% and 45.67%, respectively, indicating efficient operational management. However, the company has transitioned from negative EBIT in earlier years, reflecting a significant turnaround in profitability.

Balance Sheet

The balance sheet is strong with a very low debt-to-equity ratio of 0.0015 in TTM, indicating minimal leverage and financial risk. The return on equity (ROE) has improved significantly to 19.36% in TTM, showcasing effective use of equity to generate profits. The equity ratio stands at a healthy level, reflecting a solid capital structure with a high proportion of equity financing.

Cash Flow

Cash flow analysis reveals a decline in free cash flow growth by 10.71% in TTM, which could be a concern. However, the operating cash flow to net income ratio is strong at 1.93, indicating good cash generation relative to net income. The free cash flow to net income ratio is also healthy at 0.94, suggesting that the company is effectively converting its earnings into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	373.16M	290.51M	50.70M	0.00	0.00	0.00
Gross Profit	350.36M	270.45M	47.60M	0.00	0.00	-1.85M
EBITDA	171.17M	109.91M	-91.32M	-116.81M	-66.23M	-30.32M
Net Income	198.91M	89.16M	10.93M	-139.97M	-69.57M	-32.17M
Balance Sheet
Total Assets	1.24B	1.06B	818.36M	558.45M	626.29M	310.84M
Cash, Cash Equivalents and Short-Term Investments	731.07M	597.52M	532.18M	379.17M	438.10M	271.26M
Total Debt	9.51M	7.26M	8.09M	8.93M	8.02M	11.55M
Total Liabilities	102.22M	109.46M	39.71M	36.22M	32.72M	18.76M
Stockholders Equity	1.14B	946.38M	778.64M	522.23M	593.58M	292.08M
Cash Flow
Free Cash Flow	165.59M	119.18M	-100.60M	-153.55M	-116.27M	-40.93M
Operating Cash Flow	176.20M	123.42M	-88.80M	-100.57M	-47.94M	-26.08M
Investing Cash Flow	-153.36M	-163.44M	82.64M	-114.08M	-226.77M	-11.18M
Financing Cash Flow	-4.53M	27.01M	202.75M	35.35M	347.69M	118.02M

Krystal Biotech Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 235.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KRYS, the sentiment is Positive. The current price of 235.8 is above the 20-day moving average (MA) of 225.49, above the 50-day MA of 206.67, and above the 200-day MA of 167.16, indicating a bullish trend. The MACD of 10.86 indicates Negative momentum. The RSI at 66.25 is Neutral, neither overbought nor oversold. The STOCH value of 69.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KRYS.

Krystal Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KRYS	80 Outperform	$6.92B	35.37	19.66%	―	54.51%	275.94%
ALKS	80 Outperform	$4.63B	13.87	22.35%	―	1.08%	3.40%
PTCT	72 Outperform	$6.06B	8.76	―	―	97.54%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MLTX	41 Neutral	$1.09B	―	-54.17%	―	―	-157.74%
CRSP	40 Underperform	$5.33B	―	-25.33%	―	-81.10%	-99.21%
ACLX	40 Underperform	$3.84B	-16.52	-47.18%	―	-76.96%	-425.41%

Krystal Biotech Corporate Events

Krystal Biotech Launches VYJUVEK® in Japan

On October 22, 2025, Krystal Biotech‘s subsidiary in Japan launched VYJUVEK® for treating dystrophic epidermolysis bullosa, following its inclusion in Japan’s National Health Insurance Drug Price List. This marks a significant step in Krystal Biotech’s expansion into the Japanese market, potentially enhancing its industry positioning and offering new treatment options for patients.